JP2010505783A - 非アルコール性脂肪肝炎の治療 - Google Patents

非アルコール性脂肪肝炎の治療 Download PDF

Info

Publication number
JP2010505783A
JP2010505783A JP2009530804A JP2009530804A JP2010505783A JP 2010505783 A JP2010505783 A JP 2010505783A JP 2009530804 A JP2009530804 A JP 2009530804A JP 2009530804 A JP2009530804 A JP 2009530804A JP 2010505783 A JP2010505783 A JP 2010505783A
Authority
JP
Japan
Prior art keywords
substituted
group
aryl
heterocycloalkyl
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009530804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505783A5 (enExample
Inventor
ベラサ，ナイアラ
ドレアノ，ミシェル
トラウトバイン，クリスティアン
Original Assignee
アレス トレーディング ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレス トレーディング ソシエテ アノニム filed Critical アレス トレーディング ソシエテ アノニム
Publication of JP2010505783A publication Critical patent/JP2010505783A/ja
Publication of JP2010505783A5 publication Critical patent/JP2010505783A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009530804A 2006-10-04 2007-10-04 非アルコール性脂肪肝炎の治療 Pending JP2010505783A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84925106P 2006-10-04 2006-10-04
US90411607P 2007-02-28 2007-02-28
PCT/EP2007/008627 WO2008040548A2 (en) 2006-10-04 2007-10-04 Treatment for non-alcoholic-steatohepatitis

Publications (2)

Publication Number Publication Date
JP2010505783A true JP2010505783A (ja) 2010-02-25
JP2010505783A5 JP2010505783A5 (enExample) 2010-11-25

Family

ID=38949734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009530804A Pending JP2010505783A (ja) 2006-10-04 2007-10-04 非アルコール性脂肪肝炎の治療

Country Status (7)

Country Link
US (1) US20080194575A1 (enExample)
EP (1) EP2157975A2 (enExample)
JP (1) JP2010505783A (enExample)
AU (1) AU2007304439A1 (enExample)
CA (1) CA2664413A1 (enExample)
IL (1) IL197941A0 (enExample)
WO (1) WO2008040548A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020090967A1 (ja) * 2018-10-31 2020-05-07 東和薬品株式会社 線維化誘導遺伝子の発現抑制剤およびその用途

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
US8524212B2 (en) * 2007-10-24 2013-09-03 Mitsubishi Tanabe Pharma Corporation Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis
US20100008988A1 (en) * 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
US20120202849A1 (en) * 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
AU2011260323A1 (en) 2010-06-04 2012-11-15 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as LRRK2 modulators
KR101566091B1 (ko) 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
US8865641B2 (en) 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
CA2848711C (en) * 2011-09-16 2019-08-06 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
CA2941411A1 (en) * 2014-03-21 2015-09-24 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
CA2968215A1 (en) * 2014-08-20 2016-02-25 Yale University Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
CN105267953B (zh) * 2015-09-15 2018-08-31 浙江大学 Dll4细胞因子在制备治疗暴发性肝功能衰竭药剂中的应用
EP3445450A4 (en) * 2016-04-21 2020-01-08 CSL Limited METHOD FOR TREATING OR PREVENTING LIVER DISEASES
US20170319540A1 (en) * 2016-05-06 2017-11-09 Vivus, Inc. Methods and Compositions for the Treatment of Non-Alcoholic Steatohepatitis
EP3278802A1 (en) * 2016-08-04 2018-02-07 Metabolys New treatment for the non alcoholic steatohepatitis and fibrosis
GB201614455D0 (en) 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
TW201818964A (zh) * 2016-09-30 2018-06-01 瑞士商諾伊曼特醫療公司 使用色胺酸羥化酶抑制劑之方法
US20190351003A1 (en) * 2017-02-07 2019-11-21 The Regents Of The University Of California Methods for inhibiting nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis
WO2021073643A1 (zh) * 2019-10-18 2021-04-22 正大天晴药业集团股份有限公司 用于治疗非酒精性脂肪性肝炎的药物
CN113087757A (zh) * 2021-03-12 2021-07-09 济南大学 一种5α结构的乙型强心苷的制备及其抗肝癌应用
KR102684334B1 (ko) * 2021-08-18 2024-07-12 제이투에이치바이오텍 (주) 지방간염, 지방증 또는 섬유증의 예방 또는 치료용 복합 제제

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085396A1 (en) * 2001-04-24 2002-10-31 President And Fellows Of Harvard College Inhibition of jun kinase
JP2004523497A (ja) * 2000-12-06 2004-08-05 シグナル ファーマシューティカルズ， インコーポレイテッド Ｉｋｋ阻害剤としてのアニリノピリミジン誘導体ならびにそれに関する組成物および方法
WO2004066963A2 (en) * 2003-01-17 2004-08-12 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
JP2004534728A (ja) * 2000-12-06 2004-11-18 シグナル ファーマシューティカルズ， インコーポレイテッド Ｊｎｋ経路阻害剤としてのアニリノピリミジン誘導体、ならびにそれに関する組成物および方法
JP2005531588A (ja) * 2002-05-20 2005-10-20 ブリストル−マイヤーズ　スクイブ　カンパニー Ｃ−アリールグルコシドｓｇｌｔ２インヒビターおよび方法
US20050266391A1 (en) * 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
JP2006521394A (ja) * 2003-03-24 2006-09-21 シグナル ファーマシューティカルズ，エルエルシー Ｊｎｋを阻害することにより、炎症または代謝性症状を治療または予防する方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035703A1 (en) * 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523497A (ja) * 2000-12-06 2004-08-05 シグナル ファーマシューティカルズ， インコーポレイテッド Ｉｋｋ阻害剤としてのアニリノピリミジン誘導体ならびにそれに関する組成物および方法
JP2004534728A (ja) * 2000-12-06 2004-11-18 シグナル ファーマシューティカルズ， インコーポレイテッド Ｊｎｋ経路阻害剤としてのアニリノピリミジン誘導体、ならびにそれに関する組成物および方法
WO2002085396A1 (en) * 2001-04-24 2002-10-31 President And Fellows Of Harvard College Inhibition of jun kinase
JP2005531588A (ja) * 2002-05-20 2005-10-20 ブリストル−マイヤーズ　スクイブ　カンパニー Ｃ−アリールグルコシドｓｇｌｔ２インヒビターおよび方法
WO2004066963A2 (en) * 2003-01-17 2004-08-12 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
JP2006521394A (ja) * 2003-03-24 2006-09-21 シグナル ファーマシューティカルズ，エルエルシー Ｊｎｋを阻害することにより、炎症または代謝性症状を治療または予防する方法
US20050266391A1 (en) * 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012060143; Ａｙｍａｎ　Ｋｏｔｅｉｓｈ　ｅｔ　ａｌ: Ｂｅｓｔ　Ｐｒａｃｔｉｃｅ　＆　Ｒｅｓｅａｒｃｈ　Ｃｌｉｎｉｃａｌ　Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ １６（５）, 20021001, ｐ．６７９-６９０ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020090967A1 (ja) * 2018-10-31 2020-05-07 東和薬品株式会社 線維化誘導遺伝子の発現抑制剤およびその用途

Also Published As

Publication number Publication date
WO2008040548A2 (en) 2008-04-10
CA2664413A1 (en) 2008-04-10
IL197941A0 (en) 2009-12-24
EP2157975A2 (en) 2010-03-03
WO2008040548A3 (en) 2009-05-22
US20080194575A1 (en) 2008-08-14
AU2007304439A1 (en) 2008-04-10
AU2007304439A2 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
US20080194575A1 (en) Treatment for non-alcoholic-steatohepatitis
US12440486B2 (en) RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout
Mohammed et al. Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches
TWI814744B (zh) 包含acc抑制劑之組合療法
US11191749B2 (en) Pharmaceutical compositions for combination therapy
ES2959842T3 (es) Combinación de un agonista de PPAR con un agonista de FXR
KR102537043B1 (ko) 조합 치료요법용 약학 조성물
US20190099409A1 (en) Methods for enhancing liver regeneration
KR20160079124A (ko) 동질접합성 가족성 과콜레스테롤증의 치료
WO2020259528A1 (zh) 治疗特发性肺纤维化的方法
Ouyang et al. A natural compound jaceosidin ameliorates endoplasmic reticulum stress and insulin resistance via upregulation of SERCA2b
KR20250166323A (ko) 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합
KR102191405B1 (ko) 간 질환 예방 또는 치료용 조성물
JP7469499B2 (ja) 非アルコール性脂肪性肝炎の予防または治療用の薬学的組成物
KR20130061684A (ko) 비뇨기 동통을 수반하는 질환의 예방 또는 치료제
AU2011284256B8 (en) Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases
CN104487073A (zh) 改善肝功能的方法
RU2803733C1 (ru) Фармацевтическая композиция для предупреждения или лечения неалкогольного стеатогепатита
TW202604483A (zh) Nlrp3抑制劑在藥物中的用途
HK40130220A (zh) 用於预防或治疗非酒精性脂肪肝病的含有gpr119配体作为活性成分的药物组合物
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130423